Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7845860 in Relapsing Multiple Sclerosis
NCT07749157Phase 1Not yet recruiting
- Sponsor
- Roche
- Start
- Dec 2026
- Primary completion
- Feb 2031
01
Overview
Phase 1, open-label trial of RO7845860 in multiple sclerosis (MS) (3 arms), sponsored by Roche. Primary endpoints: Incidence and Severity of Adverse Events at 96 weeks and Change From Baseline in Columbia-Suicide Severity Rating Scale at 96 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
RO7845860
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07749157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749157.